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Background: Pain is a frequent non-motor symptom (NMS) of Parkinson’s disease (PD). We 
investigated the analgesic efficacy of prolonged release oxycodone–naloxone (OXN PR) for PD 
patients with chronic, severe pain.  
Methods: This Phase II study was conducted in 47 secondary care centres (Czech Republic, Germany, 
Poland, Hungary, Romania, Spain and UK; EudraCT 2011-002901-31, ClinicalTrials.gov NCT01439100; 
trial closed). Patients (Hoehn and Yahr Stage II–IV PD, ≥1 type of severe pain, average 24-h pain 
score ≥6 [11-point scale]) were randomised (1:1) using a validated, automated system (block size 4) 
to double-blind oral OXN PR or placebo for 16 weeks (starting dose 5 mg oxycodone /2·5 mg 
naloxone twice daily). Personnel involved in the study conduct and interpretation were blinded to 
treatment assignment. Primary endpoint was the superiority of OXN PR vs placebo for average 24-h 
pain scores (assessed on an 11-point numerical rating scale: 0 = no pain to 10 = pain as bad as you 
can imagine) at Week 16 in the full analysis population (FAP).  
Findings: Of 93 and 109 patients randomised to OXN PR and placebo, respectively, the FAP 
comprised OXN PR n=88, placebo n=106. Primary endpoint in the FAP was not met: OXN PR least 
squares (LS) mean (95% CI) 5·0 (4·5, 5·5), placebo 5·6 (5·1, 6·0); LS mean difference (95% CI) -0·6 (-
1·3, 0·0), p=0·058. Overall incidences of all-causality adverse events (60/92 [65·2%] vs 76/109 
[69·7%]), treatment-related adverse events (52/92 [56·5%] vs 62/109 [56·9%]) and serious adverse 
events (5/92 [5·4%] vs 7/109 [6·4%]) were comparable between OXN PR and placebo groups. 
Treatment-related events observed more frequently with OXN PR vs placebo were nausea (16/92 
[17·4%] vs 10/109 [9·2%] patients) and constipation (16/92 [17·4%] vs 6/109 [5·5%] patients). 
Interpretation: Although the primary endpoint, based on the FAP, was not met (p=0·058), this study 
adds to current understanding of the potential for opioid-based treatment for patients with PD-related pain 
and  warrants further research investigating the role of OXN PR in this setting. 
Funding: Mundipharma Research GmbH & Co. KG. 
 
Introduction 
In addition to the cardinal motor symptoms of Parkinson’s disease (PD), non-motor symptoms (NMS) 
are highly prevalent yet often underreported 1. NMS, which include gastrointestinal symptoms, 
neuropsychiatric symptoms, sleep disorders, visual dysfunction, hyposmia and pain, can have a 
substantial impact on patients’ quality of life 1-4. As with motor symptoms, patients often experience 
worsening in some NMS when the effects of antiparkinsonian therapy are wearing off 1,4. 
PD-related pain affects approximately 60% of patients with PD, and patients frequently report 
multiple pain types 5-7, which may include musculoskeletal, central or visceral, nocturnal, orofacial, 
and peripheral limb and abdominal pain 1. PD-related pain may be attributed to peripheral pain 
mechanisms, including motor symptoms causing or amplifying pain, and PD pathophysiology in pain 




PD-related pain from both medical and patient perspectives. PD-related pain is commonly only 
treated by increasing the doses of dopaminergic therapy. 
Although PD-related pain is more frequent and more intense than other pain observed in the 
general population, it is largely undertreated 6,7,9. Patients with PD-related pain are less likely to be 
prescribed analgesic therapy compared with individuals with chronic pain-related diseases such as 
osteoarthritis 6,7,10. The reasons for this discrepancy are largely unknown, and treatment guidelines 
for PD-related pain are currently lacking due to an absence of randomised, controlled trials 
specifically investigating analgesia in this setting 8,11,12. Given the complexity of PD pain, and the 
variety of other NMS that patients with PD frequently experience, studies are needed to ascertain 
the effectiveness and tolerability of different analgesic agents across the spectrum of PD pain types.  
World Health Organization Step-3 opioid analgesics are widely used to treat moderate-to-severe 
pain conditions of various origin13. The pain pathways mediated by dopaminergic and opioidergic 
neurons lie in close proximity in the spinal cord pain transmission pathways and may explain the 
potential role of opiates in alleviating PD-related pain.Some side effects of opioids overlap with PD 
symptoms, for example, constipation 14,15. Opioid-induced constipation arises from the interaction of 
exogenous opioids with enteric µ-opioid receptors located throughout the gastrointestinal tract 16. 
To address gastrointestinal opioid class effects, oxycodone was combined with naloxone, an opioid-
receptor antagonist in a prolonged-release formulation (OXN PR). Oral naloxone has negligible 
systemic availability due to extensive first-pass hepatic metabolism, and has been shown to 
normalise delayed gastrointestinal transit observed with oxycodone alone 17,18. OXN PR is marketed 
worldwide and its efficacy and safety have been demonstrated in a variety of non-malignant and 
cancer-related pain settings 19-26. Furthermore, OXN PR at low doses (oxycodone 5·0 mg / naloxone 
2·5 mg) has also been shown to provide effective, symptomatic relief of severe restless legs 
syndrome, and OXN PR at doses of oxycodone 10·0 / naloxone 5·0 mg has demonstrated efficacy for 
chronic pain in a small prospective study of PD patients 27,28.  
This study investigated the analgesic efficacy of OXN PR vs placebo in patients with chronic, severe 
PD-related pain, and assessed the tolerability of OXN PR and its effect on motor symptoms, NMS, 
quality of life and intake of rescue medication.  
 
Methods 
Study design and participants 
This Phase II study comprised 16-week, randomised, double-blind treatment with OXN PR or 
placebo, followed by a 4-week extension phase of open-label OXN PR aimed to transition patients to 
subsequent pain treatment at study end (Figure 1). It was performed in 47 secondary care centres in 
the Czech Republic, Germany, Poland, Hungary, Romania, Spain and UK. The study was conducted in 
accordance with the Declaration of Helsinki, International Conference on Harmonization Guidelines 
for Good Clinical Practice and the European Union Clinical Trials Directive. Procedures were 
approved by local ethics committees, and all patients provided informed, written consent prior to 




Patients were ≥25 years and had Hoehn and Yahr Stage II–IV PD, an average 24-h pain score of ≥6 on 
an 11-point numerical rating scale (NRS; over the 7 days prior to randomisation 29), severe pain in ≥1 
subsection of the Chaudhuri and Schapira pain classification system (now developed and published 
as the validated King’s PD Pain Scale 30,31) and were considered likely to benefit from WHO Step 3 
opioid therapy. Patients also received stable treatment for PD for ≥4 weeks prior to randomisation 
and did not have visual or auditory disturbances that may prevent them from completing study 
questionnaires. Women <1 year post-menopause were not pregnant or lactating and willing to use 
effective contraception throughout the study. Exclusion criteria included severe cognitive 
impairment or dementia (score of ≤24 on Mini Mental State Examination); history of psychosis 
(including hallucinations and delusions), drug or alcohol abuse; regular use of opioid-containing 
mediation in the prior 6 months; and contraindications to OXN PR or rescue medication (levodopa 
[L-DOPA] / benserazide hydrochloride tablets). Patients were also excluded with medical history or 
abnormal laboratory/electrocardiogram (ECG) parameters considered to place them at risk upon 
exposure to study medication. Please see the supplementary appendix for a full list of inclusion and 
exclusion criteria. 
 
Randomisation and masking 
Current antiparkinsonian medications were continued throughout the study. Patients were 
randomised 1:1 using blocking methodology (block size of 4) to OXN PR or matching placebo. 
Randomisation was conducted by the Sponsor in a centre-based scheme using a validated 
automated system (RPAS) that randomly assigned treatment groups to random numbers. Interactive 
response technology (IRT) was used to manage randomisation and study medication supply. During 
double-blind treatment, all patients and personnel involved in the conduct and interpretation of the 
study were blinded to treatment assignment. Treatment allocations were kept blind until the study 
was completed and after final clinical database lock, except in cases of emergency. 
 
Procedures 
Patients attended the study clinic at baseline (randomisation) and at Weeks 1, 2, 4, 8, 12, 16 (end of 
double-blind treatment/ start of open-label OXN PR phase), 18, and 20 (end of open-label phase; 
Figure 1). A safety follow-up was conducted 7–10 days after the last dose of study medication. 
Telephone calls were also conducted on Days 2, 4, 114, and 116 to check if pain scores indicated a 
need for up-titration of study medication, alertness, use of rescue medication, concomitant 
medication, changes in PD medication and to record adverse events. 
Titration of oral study medication (starting dose 5 mg oxycodone /2·5 mg naloxone twice daily, 
titrated up to 20/10 mg twice daily, according to the investigator’s opinion) was permitted at any 
time during double-blind treatment if pain was not adequately controlled (L-DOPA / benserazide 
hydrochloride tablets 100/25 mg were permitted ≤3 times/day).  
Vital signs, adverse events, compliance with study medication and use of PD medication, 




questionnaires detailed below were also assessed at each study visit with the exception of ≥1 of 9 
symptoms in the Wearing off Questionnaire (WOQ-9; assessed at baseline, Weeks, 4, 8, 12, 16, and 
end of open-label treatment), Parkinson Disease Questionnaire-8 (PDQ-8, assessed at baseline, 
Week 16 and end of open-label treatment), EQ-5D-3L (assessed at baseline, Week 16 and end of 
open-label treatment), and Hospital Anxiety and Depression Scale (HADS, assessed at baseline, 
Weeks 12, 16, and end of open-label treatment). Patient diaries for average 24-h pain score were 
completed in the 7 days prior to randomisation until Week 2, and for the 7 days preceding study 
visits thereafter. Clinical laboratory tests and 12-lead ECGs were assessed at screening, Week 16 and 
end of open-label-treatment.  
 
Outcomes 
The primary endpoint was to demonstrate the superiority of OXN PR vs placebo for average 24-h 
pain scores in the 7 days preceding Week 16 of double-blind treatment. Average 24-h pain was 
assessed on an 11-point NRS (0 = no pain to 10 = pain as bad as you can imagine) in patient diaries 29. 
Secondary endpoints included average 24-h pain scores in the 7 days preceding other study visits 
during double-blind treatment; percentage of responders (≥30% reduction from baseline) in average 
24-h pain at Week 16; and percentage of responders (‘much improved’ or ‘very much improved’, 
assessed on a 7-point scale: 1 = ‘very much improved’ to 7 = ‘very much worse’) for Clinical Global 
Impression-Improvement (CGI-I) at Week 16.  
Exploratory efficacy endpoints included percentage of responders (assessed per CGI-I) for Patient 
Global Impression-Improvement (PGI-I) at Week 16, and change from baseline to Week 16 in NMS 
Scale for PD (NMSS) total score and domain scores (NMSS item 27 [unexplained pain] was not 
assessed due to the use of more specific PD-related pain tools in this study). Change from baseline to 
Week 16 was also assessed for: total scores of the Parkinson's Disease Sleep Scale-2 (PDSS-2), 
Clinical Impression of Severity Index – Parkinson’s Disease (CISI-PD), PDQ-8, Euro-Quality of Life EQ-
5D-3L index score, anxiety and depression domains of HADS, Unified Parkinson’s Disease Rating 
Scale (UPDRS) part III (motor examination) and part IV (complications of therapy in the last week). 
Change from baseline in the percentage of patients meeting WOQ-9 and use of L-DOPA / 
benserazide hydrochloride rescue medication were also assessed. A post-hoc analysis was 
conducted to investigate changes in the PD pain subtypes, assessed using the King’s Parkinson’s 




In total, 210 patients were planned to be randomised to account for drop-outs and provide 86 
patients per treatment group in the full analysis population (FAP), which was considered sufficient to 
detect a treatment difference of 1 point in the primary endpoint (standard deviation [SD] 2 points) 




Changes in average 24-h pain scores were assessed using a Mixed Model Repeated Measures 
(MMRM) analysis, including treatment and visit as fixed effects, baseline averaged pain scores as a 
covariate, treatment by visit and baseline averaged pain score by visit as interactions and centre as a 
random effect. The primary endpoint was analysed in the FAP (patients who received ≥1 dose of 
study medication and had ≥1 post-baseline primary efficacy endpoint), with sensitivity analyses 
performed in the per-protocol population (PPP; patients who complied sufficiently with the study 
protocol). A hierarchical testing strategy was used to permit confirmatory claims to be made 
(following the pre-specified hierarchy) in the event of the primary time point being statistically 
significant. The safety population comprised all patients who received ≥1 dose of study medication.  
Responders for average 24-h pain, CGI-I and PGI-I, and percentage of patients meeting WOQ-9 were 
analysed using logistic regression, including terms for treatment and centre as factors, and baseline 
average pain score as a covariate. Differences in the use of L-DOPA / benserazide hydrochloride 
tablets were tested using Wilcoxon Rank Sum test. Other exploratory efficacy endpoints were 
analysed using ANCOVA, with treatment as a factor, baseline score as a covariate and centre as a 
random effect. Statistical analyses were performed using SAS® version 9.3 (SAS Institute, Cary, NC, 
USA) and were overseen by ML, on behalf of the Study Steering Committee (SSC) as there was no 
separate Data Monitoring Committee. Based on guidance from the SSC, a separate Data Monitoring 
Committee was not required, in line with EMA guidelines (EMEA/CHMP/EWP/5872/03 Corr), as 
safety monitoring was provided throughout the study via continuous medical oversight from the 
Sponsor and the contract research organisation (CRO; Scope International AG, Mannheim, Germany, 
funded by the sponsor). This trial is registered with EudraCT (number 2011-002901-31) and 
ClinicalTrials.gov (number NCT01439100). 
 
Role of the funding source 
KR and AO (on behalf of the sponsor) initially discussed ideas for this study with CT. MH, KR, AO (on 
behalf of the sponsor) and the SSC (JD, MH, ML [on behalf of the sponsor] together with KRC, PM-M, 
OR and CT) worked on the design, development and conduct of the study. Data were collected by 
the investigators (CT, KRC, RE, MV, MS, AK-W, MJM; the study sponsor had no role in data 
collection). The study was monitored by the CRO, who also analysed the data (in accordance with 
the statistical analysis plan, developed by the sponsor- and non-sponsor-members of the SSC). All 
authors had full access to the study data, and sponsor- and non-sponsor members of the SSC 
contributed to the interpretation of the data. This article was developed by the sponsor- and non-
sponsor authors in face-to-face meetings, telephone conversations and with support from a medical 
writer (funded by the sponsor). All sponsor- and non-sponsor authors were involved in the decision 
to submit the paper for publication. Several drafts were prepared and reviewed by all authors who 







Patients were recruited between 10 February 2012 and 5 November 2013. Of 202 patients 
randomised (OXN PR: n=93, placebo: n=109; the imbalance in randomisation resulted from sites 
recruiting small numbers of patients being unable to complete randomised blocks) 66·7% (n=62 of 
93) receiving OXN PR and 70·6% (n=77 of 109) receiving placebo completed 16 weeks of double-
blind treatment.  
Discontinuations due to lack of efficacy were more common with placebo (14 of 109 patients; 
12·8%) versus OXN PR (3 of 93 patients, 3·2%), while discontinuations due to adverse events were 
less common with placebo (10 of 109 patients; 9·2%) versus OXN PR (17 of 93 patients, 18·3%; Figure 
2). In total, 145 of 151 patients (96·0%) entering the open-label phase completed an additional 4 
weeks of treatment with OXN PR (Figure 2). 
The FAP comprised 194 of 202 (96·0%) randomised patients (OXN PR: 88 of 93 [94·6%] patients, 
placebo n=106 of 109 [97·2%] patients) while the PPP comprised 176 of 202 (87·1%) randomised 
patients (OXN PR n=78 of 93 [83·9%] patients, placebo n=98 of 109 [89·9%] patients). Demographic 
and disease characteristics were balanced between treatment groups (Table 1).  
The reduction in the primary endpoint of average 24-h pain score at Week 16 with OXN PR vs 
placebo was not statistically significant (FAP: OXN PR least squares [LS] mean [95% CI] 5·0 [4·5 to 
5·5], placebo 5·6 [5·1 to 6·0]; LS mean difference [95% CI] -0·6 [-1·3 to 0·0]; p=0·058). A notable 
advantage of OXN PR vs placebo was also seen at Week 16 in the PPP pre-defined sensitivity analysis 
of the primary endpoint (-0·9 [-1·5 to -0·2]; p=0·010). However, due to the hierarchical testing used, 
confirmatory statistical testing ended at this point. Subsequent statistical inferential testing for the 
following secondary endpoints was only exploratory. Average 24-h pain scores were lower with OXN 
PR vs placebo at Week 4 (LS mean difference [95% CI] -0·6 [-1·1 to -0·1], p=0·018), Week 8 (-0·7 [-1·2 
to -0·2], p=0·011) and Week 12 (-0·7 [-1·3, to -0·1], p=0·021) in the FAP (Figure 3). Responder rates (≥ 
30% reduction from baseline) for average 24-h pain at Week 16 were 13·7% greater with OXN PR vs 
placebo in the FAP (42 of 88 patients [47·7%] vs 36 of 106 patients [34·0%]; p=0·021; PPP: 39 of 78 
patients [50·0%] vs 30 of 98 patients [30·6%], p=0·003). Responder rates (‘much improved’ or ‘very 
much improved’) were numerically greater with OXN PR vs placebo for CGI-I (OXN PR 36·4% [32 of 
88 patients] vs placebo 26·7% [28 of 105 patients], p=0·019). 
Median (IQR) exposure to study drug was reflecting the 16-week double-blind treatment duration 
(OXN PR: 112 [79 to 113] days, placebo 112 [64 to 114] days). Mean (SD) daily dose of study 
medication was lower in the OXN PR cohort (18·8 [8·4] mg) compared with placebo (23·5 [8·9] mg). 
The average number of L-DOPA / benserazide hydrochloride 100/25 mg rescue medication tablets 
taken per day was slightly lower in the OXN PR group (0.3 (SD 0.43)) compared to placebo (0.4 (SD 
0.61)), and the median (range) total overall use over the 16 weeks was also less with OXN PR (200·0 
[0 to 19200] mg) versus placebo (500·0 [0 to 28100] mg).  
In exploratory analyses, OXN PR and placebo groups were comparable for observed change from 
baseline to Week 16 in NMSS total score and domain scores (including no negative effect of OXN PR 
on gastrointestinal function [Table 2; NMSS domain and total scores at baseline are detailed in the 




receiving OXN PR and placebo suffered very often/often from distressing dreams or distressing 
hallucinations at night, see supplementary appendix), PDQ-8, EQ-5D-3L, HADS-depression and 
anxiety, CISI-PD, UPDRS part III and part IV and WOQ-9 (Table 3). Responder rates (‘much improved’ 
or ‘very much improved’) for PGI-I (OXN PR 37·5% [33 of 88 patients], placebo 26·7% [28 of 105 
patients], p=0·022) at Week 16 were numerically greater with OXN PR vs placebo.  
Post-hoc analysis revealed that the percentage of patients with severe pain decreased from baseline 
to Week 16 for all pain types in both treatment groups. In the subgroup of patients with severe 
musculoskeletal PD pain (King’s PD Pain Scale: domain 1) at Week 16 OXN PR significantly improved 
pain compared with placebo (LS mean difference [95% CI] -0·9 [-1·7 to -0·1], p=0·023 [Baseline: OXN 
PR n=67, placebo n=77; Week 16 OXN PR n=44, placebo n=54]). Similar results were observed in 
patients with severe nocturnal pain (King’s PD Pain Scale: domain 4: -1·6 [-2·7 to -0·4], p=0·010 
[Baseline: OXN PR n=26, placebo n=37; Week 16 OXN PR n=18, placebo n=26]). There were no 
significant differences between treatment groups at Week 16 in other PD-related pain types. 
Notable improvements with OXN PR versus placebo were also in severe musculoskeletal pain and 
severe nocturnal types of PD pain in the subgroup of patients who provided assessment values at 
both baseline and Week 16 (LOCF; improvements in types of severe PD-related pain are detailed in 
the supplementary appendix). 
During the open-label treatment phase with OXN PR, patients who had received placebo during 
double-blind treatment experienced a greater reduction in average 24-h pain scores (mean [SD] 
change -1·2 [1·5] points) compared with those who received OXN PR during double-blind treatment 
(-0·3 [1·0] points). This reflects higher mean (SD) average 24-h pain scores at the start of open-label 
treatment in the prior placebo group vs OXN PR group (5·5 [2·1] vs 4·7 [2·4]), further supporting the 
clinical beneficial analgesic effect of OXN PR. 
During double-blind treatment, the overall incidences of all-causality adverse events, treatment-
related adverse events and serious adverse events were similar between treatment groups (Table 4). 
Incidences of all-causality nausea (18 of 92 patients [19·6%] vs 13 of 109 patients [11·9%]), 
constipation (16 of 92 patients [17·4%] vs 6 of 109 patients [5·5%]), vomiting (7 of 92 patients [7·6%] 
vs 3 of 109 patients [2·8%]) and hyperhidrosis (7 of 92 patients [7·6%] vs 2 of 109 patients [1·8%]) 
were more frequent in patients treated with OXN PR vs placebo (Table 4). Treatment-related nausea 
(16 of 92 patients [17·4%] vs 10 of 109 patients [9·2%]) and treatment-related constipation (16 of 92 
patients [17·4%] vs 6 of 109 patients [5·5%]) were notably higher with OXN PR vs placebo. 
Constipation was not reported as a SAE and resulted in study discontinuation in 2 of 92 patients 
(2·2%) and 0 of 109 patients randomised to OXN PR and placebo, respectively. During open-label 
treatment, the most frequent all-causality adverse events were nausea (12 of 151 patients, 7·9%), 
dizziness (11 of 151 patients, 7·3%) and fatigue (n=9 of 151 patients, 6·0%, for further details please 
see the supplementary appendix). 
No clinically relevant changes in laboratory parameters were observed. Treatment-related adverse 
events concerning vital signs included hypotension (OXN PR n=3), orthostatic hypotension (placebo 
n=1), blood pressure decrease (placebo n=1), tachycardia (OXN PR n=1) and hypertension (OXN PR 






The primary endpoint of improved average 24-h pain score with OXN PR vs placebo at Week 16 
(FAP) was not met (p=0·058). However, the PPP analysis revealed that appropriate adherence 
resulted in significantly improved 24-h average pain scores at Week 16 with OXN PR vs placebo 
(p=0.010). Assessments of 24-h pain at other timepoints during the study in FAP also indicated OXN 
PR had a positive effect on severe PD-related pain: Week 4 (p=0.018), Week 8 (p=0·011) and Week 
12 (p=0·021), although confirmatory statistical significance cannot be inferred due to the limitations 
of the hierarchical testing procedure. Other secondary endpoint data also favoured OXN PR, 
including greater responder rates for 24 h pain scores , 2·5-fold lower total use of L-DOPA rescue 
medication, and clinically relevant improvements in CGI-I and PGI-I versus placebo. Patients in the 
placebo group required higher doses of study medication and discontinued due to lack of efficacy 
more frequently compared with patients randomised to OXN PR, further supporting the beneficial 
effects of OXN PR.  
Reasons for exclusion from the PPP, including intake of considerable amounts of L-DOPA rescue 
medication observed in the placebo group only, had a notable influence on the analysis results. This 
may be explained by motor fluctuations and dyskinesia-related pain being particularly responsive to 
dopaminergic therapy, compared with other PD pain types 1,32, although we tried to exclude purely 
‘off-period’-related pain. Improvement in pain over time, which is anticipated in severe pain, may 
also have contributed to the failure to meet the primary endpoint. As was observed in the placebo 
group, pain severity decreased over the course of the study. Severe PD-related pain was an inclusion 
criterion in this study, but it is unlikely that patients will tolerate severe pain for more than a few 
weeks. This may explain the drop-out rate and missing data at Week 16. Therefore, assessment of 
change in less severe pain may have better reflected the true treatment effect. In addition, the 
higher average daily dose of study medication observed in the placebo group may have influenced 
analgesic response.  
The heterogeneity of PD pain types may also have impacted the outcome of this study. Specific pain-
related symptom assessment using the King’s PD Pain Scale, revealed that OXN PR was associated 
with particular improvements in severe musculoskeletal pain (p=0·023) and severe nocturnal pain 
(p=0·010), the two most common PD-related pain types observed at baseline. L-DOPA rescue 
medication, used at a higher total dose in the placebo group, may have influenced ‘off-period’-pain 
and the associated findings in these patients. It is noteworthy that this study represents the first 
field testing of the King’s PD Pain scale, and captures the heterogeneous nature of PD-related pain as 
previously identified 1,31. In the validation study of the King’s PD Pain Scale, highest pain scores 
compared with controls were observed in musculoskeletal and nocturnal pain domains 31. The 
efficacy of the OXN PR in these pain domains in the present study supports the validity of the scale in 
this population. 
Based on the pathophysiology and diversity of PD pain, it is likely a variety of management 
approaches are warranted. Nociceptive PD pain arises due to activation of nociceptors in non-
neuronal tissue, while neuropathic PD pain results in part from basal ganglia dysfunction and 
dopaminergic denervation 8,11. Patients with PD neuropathic pain have lower than normal pain 




pain-induced cerebral activations 33,34. However, observations that apomorphine has little effect on 
neuropathic pain processing suggests the importance of other systems 11,35. Opioids and other 
analgesics with effects on the descending inhibitory pain pathways could therefore be effective 
against nociceptive and neuropathic pain 11. Many patients experience a complex array of pain and 
in clinical practice it is important to distinguish ‘off-period’ pain, which can be effectively managed 
with dopaminergic therapy, from other types of PD pain to optimise treatment strategies.  
Worsening of NMS with active treatment was not observed in this study. There were no negative 
effects on sleep, mood/cognition, sexual function and perceptual problems/hallucinations. 
Constipation, an anticipated side effect, given it affects many patients with PD and is a common class 
effect of opioid analgesics 15,16, was not particularly aggravated by OXN PR. Although as an adverse 
event constipation was more frequent with OXN PR vs placebo, it rarely resulted in discontinuation 
of study medication and in no case was it considered an SAE. These findings contrast other opioid 
studies, in which constipation is estimated to affect 80% of individuals; this difference may relate to 
the unique mechanism of action of OXN PR 18. Other common adverse events observed were 
consistent with those documented with OXN PR in other pain settings, and included nausea, 
somnolence, dizziness and fatigue 36. It is noteworthy that the mean daily dose of OXN PR during 
double-blind treatment (18·8 mg) was substantially lower than the highest dose of 120 mg/day 
permitted in other placebo-controlled, double-blind trials in patients with moderate-to-severe 
chronic pain 19,36. 
Oxycodone is known to have addictive properties in common with all opioids and, as a Scheduled 
Drug, is subject to stringent controls and regulations on its prescription, storage and distribution. 
OXN PR combines oxycodone with the antagonist naloxone, which further reduces its potential for 
abuse 37. In addition, this 16-week study found no evidence for PD patients increasing their mean 
OXN PR dose, indicating patients were not up-titrating to higher opioid doses or becoming addicted 
to oxycodone. 
To our knowledge this is the first randomised, controlled trial specifically designed to investigate 
treatment of PD-related pain. One randomised, controlled trial of rotigotine with pain as a post-hoc 
analysis showed improvements in pain associated, which were attributed to benefits in motor 
function and sleep disturbances 38. In addition, a small prospective study of PD patients 
demonstrated efficacy of OXN PR 10/5 mg for chronic pain 28. As the first trial of its kind, the 
statistical methods are of an exploratory nature. While the p-values for the secondary endpoints are 
below 0·05, statistical significance could not be inferred due to the limitations of the hierarchical 
testing procedure. 
The current study was limited by the restrictive inclusion criteria of very severe pain using a non-PD-
specific pain scale. Lack of prior randomised controlled studies of PD-related pain hampered 
estimations of sample size and may have resulted in the trial being underpowered in terms of the 
margin of effect. Other limitations include L-DOPA as rescue medication, which may have impacted 
some types of PD-related pain, the imbalance in randomisation (OXN PR n=93, placebo n=109) and 
quantity of missing data. Also, intermittent (or incidental) off-period related pain could not be 
excluded as this may occur in any patient with fluctuating PD. Further studies of OXN PR for PD-




investigation of higher doses which reflect the prescribing information for OXN PR in chronic pain, 
and studies comparing the analgesia obtained from OXN PR with other treatments and non-
pharmacologic interventions.  
 
Research in Context 
Evidence before this study 
PubMed and Cochrane Database were searched up to July 2011 using the key words ‘pain’, 
‘Parkinson’, and ’randomised controlled trial’. No placebo-controlled randomised trials were 
identified which were specifically designed to investigate the analgesic efficacy of opioids in patients 
with Parkinson’s disease (PD)-related pain and no trials used assessment of pain as the primary 
endpoint for efficacy. These findings are in agreement with the publication The Movement Disorder 
Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of 
Parkinson's disease published in 2011. 
Added value of this study  
A subsequent search of PubMed, conducted in May 2015 using the terms ‘pain’, ‘Parkinson’s’ and 
‘randomi*’ in titles/abstracts revealed one randomised, controlled trial with pain as a post-hoc 
endpoint, but no trials were identified with pain as a primary endpoint.  
To our knowledge, this Phase II study is the first randomised, controlled trial specifically designed to 
investigate medical treatment of PD-related pain. While the primary endpoint was not met, 
secondary endpoint data indicate a potential utility of OXN PR in this setting, which requires further 
investigation in randomised, controlled trials. Assessment of pain types in this study was based on 
the first, validated scale for PD-related pain, and provides insight into the heterogeneity of PD pain 
as well as the types of PD-related pain for which OXN PR may have various positive effects. This 
study adds to the limited knowledge base of the efficacy and safety of opioid-based treatment of 
patients with PD suffering from complex pain. Since the submission of this paper, a study was 
published that supports the positive effects of OXN PR on PD-related pain, although this was limited 
by the open-label design and small (n=16) number of patients. 
Implications of all available evidence 
Effective diagnosis and management of PD-related pain is essential to lessen the burden of this 
disease. The results of this study increase the evidence-base for the management of PD-related pain 
and in particular will help to guide the design of future trials in this setting, and ultimately lead to 
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Tables and figures 
Table 1. Patient demographic and clinical characteristics at baseline (full analysis population) 




Age, years; mean (SD) 66·7 (8·9) 67.5 (8·1) 
Male / female, n (%) 43 (48·9) / 45 (51·1) 57 (53·8) / 49 (46·2) 
MMSE score, mean (SD) 28·6 (1·5) 28·6 (1·5) 
UPDRS score, mean (SD)   
            Part III 30·9 (14) 30·7 (12) 
            Part IV 5·1 (3·6) 4·9 (3·8) 
Hoehn and Yahr classification, n (%)   
            Stage 2 20 (22·7) 33 (31·1) 
            Stage 2·5 27 (30·7) 33 (31·1) 
            Stage 3 35 (39·8) 28 (26·4) 
            Stage 4 6 (6·8) 12 (11·3) 
Duration of PD, years; mean (SD) 6·9 (5·2) 6·7 (4·2) 
Duration of PD pain, years; mean (SD) 3·4 (3·0) 3·4 (2·8) 
Baseline current PD medication use 
Patients with ≥1 current PD medication 83 (94·3) 99 (93·4) 
Anti-Parkinson Drugs 82 ( 93·2) 97 (91·5) 
            Dopaminergic Agents 82 ( 93·2) 97 (91·5) 
PD-related pain characteristics 
Average 24-h pain score (0 = no pain to 10 = pain as 
bad as you can imagine); mean (SD) 
7·3 (1·0) 7·3 (0·9) 
Severe types of PD pain, n (%)a   
            Musculoskeletal pain 67 (76·1) 77 (72·6) 




            Fluctuation-related pain 26 (29·5) 34 (32·1) 
            Nocturnal pain 26 (29·5) 37 (34·9) 
            Orofacial pain 2 (2·3) 6 (5·7) 
            Pain in limbs with discolouration 17 (19·3) 20 (18·9) 
Patients currently receiving ≥1 PD pain medication, 
n (%) 
64 (72·7) 74 (69·8) 
            Anti-inflammatory /antirheumatic agents 35 (39·8) 47 (44·3) 
            Other analgesic and antipyrectic agents 24 (27·3) 29 (27·4) 
            Dopaminergic agents 10 (11·4) 13 (12·3) 
MMSE, mini mental state examination (score range 0–30; ≥27 indicates normal cognition); PD, 
Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale (part III: motor examination 
[score range 0–56], part IV: complications of therapy in past week [score range 0–23], higher score 
indicates greater disability/complications) 




Table 2. Non-Motor Symptom Scale (NMSS, LOCF; Full Analysis Population) 
Change in domain score:  
Baseline to Week 16 
OXN PR (N=88) 
Least Squares mean (95% CI) 
Placebo (N=106) 
Least Squares mean (95% CI) 
OXN PR vs placebo 
Least Squares mean difference (95% CI) 
P valueb 
Cardiovascular 0·1 (-0·5, 0·7) 0·1 (-0·4, 0·7) -0·1 (-0·8, 0·7) 0·880 
Sleep/fatigue -3·0 (-4·5, -1·5) -1·6 (-3·1, -0·2) -1·4 (-3·0, 0·2) 0·077 
Mood/cognition -1·1 (-2·7, 0·5) -1·3 (-2·8, 0·2) 0·2 (-2·1, 2·4) 0·887 
Perceptual 
problems/hallucinations 
0·3 (-0·1, 0·8) 0·1 (-0·4, 0·5) 0·3 (0·0, 0·5) 0·059 
Attention/memory -0·2 (-0·9,0·5) -2·0 (-10·9, 0·4) 0·1 (-0·8, 1·0) 0·882 
Gastrointestinal functiona -0·3 (-1·0, 0·3) -0·7 (-1·3, -0·1) 0·3 (-0·5, 1·2) 0·407 
Urinary function -1·6 (-2·9, -0·2) -0·7 (-2·0, 0·6) -0·9 (-2·1, 0·3) 0·123 
Sexual function -0·4 (-1·0, 0·1) -0·2 (-0·8, 0·3) -0·2 (-1·0, 0·5) 0·590 
Miscellaneous -2·3 (-3·7, -1·0) -2·1 (-3·4, -0·9) -0·2 (-1·5, 1·2) 0·789 
Total score -8·6 (-13·5, -3·7) -7·1 (-11·8, -2·5) -1·5 (-6·9, 4·0) 0·593 
NMSS domains were scored by multiplying the severity (rated as 0 = ’none’ to 3 = ‘severe’) and frequency (rated as 1 = ‘rarely’ to 4 = ‘very frequent’) 
recorded for each item 
aIncludes Question 21: Does the patient suffer from constipation (bowel action <3 times weekly)?; mean (SD) change from baseline to Week 16 (LOCF) was 
OXN PR -0·1 (1·9), placebo -0·3 (2·3). 




Table 3. Summary of findings for exploratory endpoints (LOCF; Full Analysis Population) 
Change in score:  
Baseline to Week 16 
OXN PR (N=88) 
Least Squares mean (95% CI) 
Placebo (N=106) 
Least Squares mean (95% CI) 
OXN PR vs placebo 




   OXN PR n=88, placebo n=105 
-6·2 (-8·2, -4·3) -4·9 (-6·8, -3·1) -1·3 (-3·5, 1·0) 0·258 
PDQ-8 
   OXN PR n=76, placebo n=91 
-6·5 (-9.3, -3·7) -3·2 (-5·9. -0·6) -3·3 (-6·7, 0·1) 0·060 
EQ-5D-3L 
   OXN PR n=76, placebo n=92 
0·2 (0·1, 0·3) 0·1 (0·1, 0·2) 0·1 (0·0, 0·15) 0·057 
HADS-anxietya 
   OXN PR n=80, placebo n=96 
0·7 (0·2, 1·2) 0·0 (-0·5, 0·4) 0·7 (0·1, 1·3) 0·021 
HADS-depression 
   OXN PR n=80, placebo n=96 
0·2 (-0·3, 0·7) -0·2 (-0·6, 0·3) 0·3 (-0·3, 0·9) 0·267 
CISI-PD 
   OXN PR n=68, placebo n=90 
-0·5 (-1·0, 0·1) -0·4 (-0·9, 0·0) -0·1 (-0·6, 0·5) 0·810 
UPDRS part IIIb 
   OXN PR n=88, placebo n=106 
-2·7 (-4·5, -1·0) -2·7 (-4·3, -1·2) 0·0 (-1·9, 2·0) 0·975 
UPDRS part IVb 
   OXN PR n=67, placebo n=90 





   OXN PR n=85, placebo n=104 
71/85 (83·5%)d 89/104 (85·6%)d 0·9 (0·5, 1·6) 0·694 
CISI-PD, Clinical Impression of Severity Index – Parkinson’s disease; EQ-5D-3L, Euro-Quality of Life; HADS, Hospital Anxiety and Depression Scale; PDQ-8, 
Parkinson Disease Questionnaire-8; PDSS-2, Parkinson's Disease Sleep Scale-2; UPDRS, Unified Parkinson’s Disease Rating Scale; WOQ-9, Wearing-Off 
Questionnaire. 
aThe small difference of 0.7 (3%) on a scale of 0 to 21 is not considered clinically relevant. bPart III: motor examination, Part IV: complications of therapy 
(includes dyskinesia, which was examined in a post-hoc analysis) 
cPatients meeting WOQ-9 wearing off criteria (≥1 symptom in the WOQ-9 with improvement after the next dose of anti-Parkinsonian medication) at Week 
16, odds ratio (95% CI) 




Table 4. Summary of adverse events occurring during double-blind treatment (safety population) 
Adverse events and serious adverse events OXN PR (N=92)  
n (%) 
Placebo (N=109)  
n (%) 
Adverse events 
Patients with ≥1 AE 60 (65·2) 76 (69·7) 
Patients with ≥1 treatment-related AEa 52 (56·5) 62 (56·9) 
Patients with ≥1 treatment-related severe AEa 6 (6·5) 5 (4·6) 
Most frequent all-causality AEsc   
   Nausea 18 (19·6) 13 (11·9) 
   Somnolence 12 (13·0) 15 (13·8) 
   Dizziness 12 (13·0) 12 (11·0) 
   Constipation 16 (17·4) 6 (5·5) 
   Fatigue 7 (7·6) 10 (9·2) 
   Headache 6 (6·5) 9 (8·3) 
   Dry mouth 5 (5·4) 5 (4·6) 
   Vertigo 6 (6·5) 4 (3·7) 
   Vomiting 7 (7·6) 3 (2·8) 
   Diarrhoea 2 (2·2) 7 (6·4) 
   Hyperhidrosis 7 (7·6) 2 (1·8) 
   Fall 5 (5·4) 3 (2·8) 
Serious adverse events 
Patients with ≥1 SAEb 5 (5·4) 7 (6·4) 
   Number of SAEs 9 10 
Patients with ≥1 treatment-related SAEa 2 (2·2) 2 (1·8) 
SAEsd   




   Benign prostatic hyperplasia 0 1 (0.9) 
   Cholelithiasis 1 (1.1) 0 
   Cystitis 1 (1.1) 0 
   Diarrhoea 0 1 (0.9) 
   Endometrial hypertrophy 0 1 (0.9) 
   Loss of consciousness 1 (1.1) 0 
   Lumbar spine stenosis 0 1 (0.9) 
   Melaena 1 (1.1) 0 
   Oedema (peripheral) 0 1 (0.9) 
   Osteoarthritis 0 1 (0.9) 
   Pain in extremity 0 1 (0.9) 
   Pancreatitis, acute 1 (1.1) 0 
   Pneumonia 0 1 (0.9) 
   Pyelocaliectasis 1 (1.1) 0 
   Pyelonephritis 1 (1.1) 0 
   Rib fracture 1 (1.1) 0 
   Spondylolisthesis 0 1 (0.9) 
   Urinary retention 1 (1.1) 0 
Deaths 
Patients who died 0 0 
AE, adverse event; SAE, serious adverse event 
aInvestigator considered the AE to be ‘unlikely’, ‘possibly’, ‘probably’, or ‘definitely’ related to study 
medication 
bTwelve treatment-emergent SAEs were judged to be severe and all either recovered or recovered 
with sequelae with the exception of one case of atrial fibrillation which was ongoing in a patient 
receiving placebo 
cAEs occurring ≥5% in either treatment group (MedDRA preferred term) 
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